. Author manuscript; available in PMC: 2019 Sep 1.

Published in final edited form as: Pediatr Infect Dis J. 2018 Sep;37(9):923–929. doi: 10.1097/INF.0000000000001913

Table 4.

Outcomes by resistance status

A	Invasive candidiasis (N=110) – All infants
	Infants with Candida isolate(s) having a low MIC^a (n=46)	Infants with Candida isolate(s) having a high MIC^a (n=64)	P
Death prior to discharge (%)^b	15/46 (33)	21/64 (33)	0.88
Death at 18–22 months (%)^b	17/44 (39)	22/57 (39)	0.93
NDI at 18-22 months(%)^c	11/25 (44)	9/35 (26)	0.88
Death or NDI at 18–22 months (%)^c	28/42 (67)	31/57 (54)	0.47
B	Infants with invasive candidiasis and treated with fluconazole (N=34)
	*Infants with Candida* isolate(s) having a low fluconazole MIC**^a (n=26)	*Infants with Candida* isolate(s) having a high fluconazole MIC**^a (n=8)	P
Death prior to discharge (%)^b	8/26 (31)	2/8 (38)	0.43
Death at 18-22 months (%)^b	10/25 (40)	3/7 (43)	0.73
NDI at 18–22 months (%)^c	3/14 (21)	1/4 (25)	0.57
Death or NDI at 18–22 months (%)^c	13/24 (54)	4/7 (31)	0.27
Therapy Failure^b (%)	5/25 (20)	4/8 (50)	0.19

Low and high antifungal MIC defined in Table 1

Adjusting for gestational age

Adjusting for Bayley cohort and gestational age